Member Info for RayPointer

For people new to Scancell, the SCIB1 trial in combination with Keytruda is approved to go ahead in both UK and US.
The trial in the UK actually started at Nottingham but no patients were recruited and then the pandemic happened so recruitment was suspended.
So we are just waiting for recruitment to restart.

This was originally intended as a multi-centre trial in the US but it took years for the FDA to approve the Ichor device used for delivery.
So, in the end, Scancell started the trial in the UK (Nottingham).

The position now is that
a) The Ichor device is now approved in the US
b) We have several UK locations that are just awaiting the green light to re-start
c) US trial ?

Hasiba
I agree with most of what you say.
However, I wouldn't put it past Lindy in coming up with a solution that stands out from the rest of the pack.
We know she is targeting the N protein but what we don't know is how difficult it is to target this protein.
Maybe it needs more powerful response than that required for the S protein that is very isolated and may well exhibit easier targets.
So maybe Immunobody allied with Avidimab provides the T Cell potency that is required.

Influenza has similar central proteins that Sarah Gilbert's team at Oxford targeted with a vaccine.

https://www.theguardian.com/society/2011/feb/06/flu-universal-vaccine-test-success

"If used widely a universal flu vaccine could prevent pandemics, such as the swine flu outbreaks of recent years, and end the need for a seasonal flu jab.
The problem with flu is that you've got lots of different strains and they keep changing," said Adrian Hill, director of the Jenner Institute. "Occasionally one comes out of wildfowl or pigs and we're not immune to it. We need new vaccines and we can't make them fast enough.
A universal vaccine would save the time and money now needed to create vaccines to fight whatever particular virus has emerged in any year. The government spent an estimated £1.2bn in preparing for the swine flu outbreak of last winter."

I believe this is the relevant clinical trial that did not meet its endpoints so was abandoned

https://clinicaltrials.gov/ct2/show/study/NCT03880474

So maybe a promising approach just didn't create the potency of T Cell response required. High avidity of T Cells may be the key to this.

One thing that both WHI and ST cannot predict is how Leon is planning to use all this cash that is piling up.
I can't see him keeping it under the bed. It will be used to employ more elephants or maybe kangaroos :-)

Surely that Surrey mud would be of the exquisite variety though.
Couldn't resist :-)

I think we all know the risks in investing in a company like SCLP. At least I hope we do.
The downside is if all the trials fail then it will be worth nowt. The maximum upside is if all trials succeed and to such an extent that they beat the current accepted standard of care by some margin.

Just taking one example, the SCIB1 combo trial, which from memory Lindy is aiming for 60% efficacy as opposed to the current Keytruda alone of around 30%. We know from the p1/2 SCIB1 trial conducted by Scancell that this may well be an achievable target. What price Scancell if that target is achieved especially since SCIB1 is not expected to add to the known side effects of Keytruda.

Then we have a Modi1 trial starting soon (we are continually being told) that is aimed at 4 hard to treat cancers. What price if just one of these trials within a trial is sccuessful.

etc, etc , etc down the extensive pipeline Scancell now hold.

So, as investors we have a choice of how to play this.
One approach would be to await for the 3 expected trials that we are told will start this year and just see what happens to the SP.
I certainly wouldn't rule out taking some profits before results are due but I won't set a specific SP for this as the price action of having 3 trials underway is nigh on impossible to predict. Add to that a deal with whoever on Covidity (my favourite is CEPI), then there's no telling what fireworks that will produce in the Surrey Hills :-)

Thursdays are not possible now since Lindy uses the company jet to do her weekly shop in Paris :-)

Long weekends is a sign of a lifestyle BOD :-)

Yeah, good for Albert.
He's beginning to get technical :-)

It's a sobering thought that the world could have gone much further towards solving the problem globally by distriburing vaccines evenly throughout the world.

If Scancell end up with a choice of partners and one is CEPI, I really hope that they choose CEPI.

Hasiba, did you get the lifestyle idea by reading comments on the VAL BB?

Let's not forget that the delivery peptides also need to be manufactured.
Then the DNA plasmid has to be conjugated with the peptides and re-tested.
This could be possibly be adding to the timelines.

C7, I hope you're not missing your birthday by having a long sleep :-)
Happy birthday and many of them.

Nice one bill

Of course, Avidimab can also act as an ADC.

https://www.scancell.co.uk/avidimab

"Additionally, as the same glycans can be expressed by a wide range of proteins and lipids, the mAbs can be simultaneously used for drug delivery (antibody drug conjugates: ADC), as chimeric antigen receptor T cells (CAR-T) or for redirected T cell killing. The mAbs could therefore be a combination therapy in their own right."

Didn't Lindy say that she thought Avidimab was unique. I wonder if she was referring to this combination aspect.

If you two ever meet for a beer, make sure it's filtered :-)

LOL
You're welcome crumbs

There is a collaboration between Deep Matter and the Nottingham Uni school of chemistry but I can't find anything relating to vaccine development

https://www.deepmatter.io/media/fqtbq14z/university-of-nottingham-further-collaboration.pdf

Are you confusing Deepmatter with Deepmind?
Deepmind are the company that cracked the protein folding problem recently. I would imagine Lindy might have an eye on this breakthrough

https://www.nature.com/articles/d41586-020-03348-4

Moonparty, don't forget the year

so 21/4/3132 for next news

No worries, we will soon be monetising assets

Cliff is a time lord